Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
American Journal of Hematology|October 15, 2013
Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup studyLiesbeth C de Wreede, Maggie Watson, Marleen van Os, et al.
Experimental Hematology|August 12, 2020
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 studyFatemeh Saberi Hosnijeh, Lina van der Straten, Arnon P Kater, et al.
Bone Marrow Transplantation|March 28, 2023
The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMTOlivier Tournilhac, Michel van Gelder, Dirk-Jan Eikema, et al.
Blood|May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
American Journal of Hematology|September 20, 2016
Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractoryAlbertine E Donker, Charlotte C M Schaap, Vera M J Novotny, et al.
Haematologica|August 8, 2024
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III studyDietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, et al.
The Lancet. Haematology|March 3, 2022
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trialSabina Kersting, Julie Dubois, Kazem Nasserinejad, et al.
Blood|June 26, 2023
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLLLina van der Straten, Claudia A M Stege, Sabina Kersting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A studyMonique Terwijn, Wim L J van Putten, Angèle Kelder, et al.
Pageof 6